Owing to the propensity of MEK to evolve an array of activating mutations, our results support the co-targeting of alternative MAPK pathway members in conjunction with BRAF inhibitors for patients with high-grade, BRAFV600E-driven melanoma. The gene discussed is MAP2K7; the disease is melanoma.